Climadinone Uno, 30 pcs.
€1.00
Out of stock
(E-mail when Stock is available)
Pharmacotherapeutic group
Antimicrobial agent of plant origin.
TAC code: G02CX04
Pharmacological properties
Pharmacodynamics
. The mechanism of action and constituent components of the rhizomes of Cymicifuga cysticum that contribute to the relief of menopausal symptoms are unknown.
Clinical and pharmacological studies show that administration of cymicifuga cysticum rhizome extract reduces clinical manifestations of menopausal symptoms such as hot flashes and excessive sweating.
Pharmacokinetics
No data available.
Indications
Climadinone® is indicated for the relief of menopausal symptoms such as hot flashes and excessive sweating.
Active ingredient
Cymicifuga cysticum rhizome extract
Composition
1 tablet of the drug contains:
Active ingredient:
Cimicifuga cystic rhizome extract dry* (5-10 : 1) – 2.8 mg
Associates:
lactose monohydrate, calcium hydrophosphate dihydrate, potato starch, magnesium stearate, talc, titanium dioxide (E 171), iron oxide yellow dye (E 172), iron oxide red dye (E 172), macrogol 6000, ammonium methacrylate copolymer (type A)**.
Dry extract is obtained from the rhizomes of Cimicifuga racemosa (L.) Nutt. Ranunculaceae by extraction with ethanol (ethyl alcohol) 58% by volume.
** – contains: Ammonium methacrylate copolymer (type A), sorbic acid, sodium hydroxide.
How to take, the dosage
Overly, 1 tablet daily, 2 times a day at the same time (morning and evening).
Tablets should be swallowed without chewing, drinking a small amount of water.
The drug Climadinone® should not be used for more than six months without medical advice.
Application of the drug in special clinical groups
Children and adolescents under 18 years of age
The use of Climadinone® in children and adolescents under 18 years of age is not indicated.
In patients with renal impairment
There are insufficient clinical data for specific recommendations on the dosing regimen of the drug in patients with renal impairment.
In patients with hepatic impairment
In patients with hepatic impairment, use of Climadinone® only after consulting a physician.
Use the drug only according to the indication, the route of administration and the doses described in the instructions. If there is no effect of the therapy or if the condition worsens, consult a physician.
Interaction
Interaction with other drugs is currently not known.
Special Instructions
Klimadinone® should be used with extreme caution in patients with liver dysfunction. If symptoms of liver damage occur (jaundice of skin and sclerae, fatigue, loss of appetite, darkened urine, nausea, vomiting, pains in upper abdomen), stop taking the drug and consult a physician immediately.
Patients who are or were treated for breast cancer or other hormone-dependent tumors should not take Climadinone® without consulting their physician.
In case of bleeding from the genital tract or other symptoms the patient should immediately consult a physician.
Climadinone® should not be taken simultaneously with estrogens without prior consultation with a physician.
For patients with diabetes: 1 tablet contains less than 0.04 “bread” units (BE).
Influence on ability to drive vehicles and mechanisms
Studies of the effect of Climadinone® on ability to drive vehicles and mechanisms have not been conducted.
Synopsis
Round biconvex-shaped, film-coated tablets with a pink color with a brown tint.
Contraindications
Hypersensitivity to the active component and/or any excipient of the drug.
Pregnancy and breast-feeding.
Age under 18 years.
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (the drug contains lactose).
With caution: in patients with liver disease (only after examination of liver function).
Side effects
During therapy with cimicifuga drugs, cases of liver dysfunction (including hepatitis, jaundice, increased liver transaminase activity) have been reported. Skin reactions (urticaria, skin itching, skin rash), facial edema, peripheral edema, gastrointestinal disorders (e.g., dyspepsia, diarrhea) have also been reported.
Based on the available data it is impossible to estimate the frequency of adverse reactions. If you experience or worsen the adverse reactions specified in the instructions, or if you notice any other adverse reactions not specified in the instructions, please inform your physician.
Overdose
No cases of overdose have been registered. In case of overdose – symptomatic treatment.
Pregnancy use
Klimadinone® is contraindicated during pregnancy and breastfeeding.
Weight | 0.024 kg |
---|---|
Shelf life | 3 years. Do not use after the expiration date. |
Conditions of storage | In the original package (blister, cardboard package) at a temperature not exceeding 25 ° C. Keep out of reach of children! |
Manufacturer | Germany |
Medication form | pills |
Related products
Gynecology and Obstetrics
Prepidil, intracervical gel 0.5 mg/3 g syringes with catheter
Buy Climadinone Uno, 30 pcs. with delivery to USA, UK, Europe and over 120 other countries.